GleamWall
中文EN

PSNL Personalis, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1527753 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY16.9%
TTM net income YoY-61.5%
TTM EPS YoY-39.8%
Revenue 3-yr CAGR4.6%
Net income 3-yr CAGR—

Margins

Gross margin16.7%
Operating margin-156.7%
Net margin-147.7%
FCF margin-133.3%
EBITDA margin-144.6%

Returns

ROE-62.1%
ROA-44.7%
ROIC (approx.)-84.8%
Asset turnover0.30x

Leverage & solvency

Liabilities / assets27.1%
Debt / equity0.00x
Current ratio4.53x
Interest coverage-683.98x

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue12.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$25.60M$22.36M$15.47M$17.34M$14.49M$17.20M$20.61M$16.80M
Cost of revenue$19.03M$17.61M$15.19M$15.45M$12.58M$12.45M$13.40M$12.25M
Gross profit$6.57M$4.74M$281,000$1.90M$1.91M$4.76M$7.21M$4.55M
R&D expense$16.07M$16.34M$14.54M$13.07M$12.17M$12.38M$12.64M$11.49M
SG&A expense$26.01M$22.00M$17.90M$14.09M$13.03M$14.18M$12.26M$11.17M
Operating income-$35.52M-$33.59M-$32.16M-$25.27M-$23.29M-$21.80M-$17.70M-$18.11M
Interest expense$36,000$37,000$47,000$65,000$64,000$48,000$28,000-$1,000
Pretax income-$33.80M-$31.68M-$30.02M-$23.80M-$21.65M-$20.05M-$15.74M-$16.42M
Income tax$3,000$5,000$16,000$9,000$3,000$2,000$7,000$4,000
Net income-$33.80M-$31.68M-$30.03M-$23.81M-$21.65M-$20.06M-$15.75M-$16.43M
EBITDA-$33.04M-$31.18M-$29.79M-$22.80M-$20.89M-$19.27M-$15.11M-$15.57M
EPS (basic)-0.32-0.30-0.29—-0.24-0.23-0.18—
EPS (diluted)-0.32-0.30-0.29—-0.24-0.23-0.18—
Weighted avg. shares (diluted)107.21M105.42M104.19M—88.70M88.52M87.46M—
Balance sheet
Cash & equivalents$98.27M$93.97M$73.59M$124.25M$49.97M$53.37M$71.00M$91.42M
Short-term investments$92.33M$118.69M$159.62M$115.71M$100.54M$119.86M$114.69M$93.59M
Receivables$18.04M$15.10M$13.02M$16.20M$14.38M$9.95M$10.97M$8.14M
Current assets$223.05M$245.05M$258.20M$267.95M$174.40M$193.34M$206.42M$203.01M
PP&E, net$50.32M$48.57M$48.44M$44.81M$47.00M$45.81M$47.99M$48.27M
Total assets$291.60M$312.13M$325.39M$334.16M$242.84M$258.68M$273.31M$270.27M
Current liabilities$49.27M$46.38M$39.05M$39.63M$36.16M$31.72M$29.89M$31.13M
Total liabilities$78.93M$76.97M$70.63M$72.98M$71.42M$67.85M$65.96M$67.31M
Shareholders' equity$212.67M$235.16M$254.76M$261.19M$171.41M$190.83M$207.34M$202.96M
Shares outstanding108.38M106.37M104.69M102.48M88.75M88.65M88.32M85.17M
Cash flow statement
Operating cash flow-$27.07M-$25.77M-$22.48M-$22.25M-$21.80M-$12.94M-$17.96M-$7.80M
Capital expenditure$3.07M$3.78M$3.19M$77,000$1.63M$290,000$2.51M$1.25M
Free cash flow-$30.14M-$29.55M-$25.67M-$22.32M-$23.43M-$13.22M-$20.47M-$9.04M
Investing cash flow$24.01M$38.16M-$46.01M-$14.38M$18.72M-$4.37M-$22.54M-$26.18M
Financing cash flow$7.37M$7.99M$17.83M$110.89M-$317,000-$327,000$20.09M$49.60M
Depreciation & amortization$2.48M$2.41M$2.37M$2.46M$2.40M$2.53M$2.59M$2.54M
Stock-based compensation$3.91M$3.98M$2.55M$2.30M$2.08M$2.83M$2.22M$2.67M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.